CJC-1295 + Ipamorelin Blend vs Ipamorelin
CJC-1295 + Ipamorelin Blend (Combination product: GHRH analog (CJC-1295) + GHRP/ghrelin-receptor agonist (ipamorelin)) and Ipamorelin (Growth-hormone secretagogue (GHRP) / ghrelin receptor agonist) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | CJC-1295 + Ipamorelin Blend | Ipamorelin |
|---|---|---|
| Compound class | Combination product: GHRH analog (CJC-1295) + GHRP/ghrelin-receptor agonist (ipamorelin) | Growth-hormone secretagogue (GHRP) / ghrelin receptor agonist |
| Research category | Growth & GH-Axis | Growth & GH-Axis |
| Length (amino acids) | Not documented | 5 amino acids |
| Molecular weight | Not documented | 711.9 g/mol |
| Half-life | Not documented | ~2 hours (reported approximately 120 minutes) |
| Origin | This is not a single molecule but a formulated blend combining CJC-1295 (a GHRH analog) with ipamorelin (a selective ghrelin-receptor GH secretagogue). Blends are commonly prepared in research/compounding contexts to combine two complementary GH-stimulating mechanisms. | Ipamorelin is a synthetic pentapeptide developed in the 1990s (originally by Novo Nordisk) as a selective growth-hormone secretagogue. It was designed to stimulate GH release with minimal off-target hormonal effects. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How CJC-1295 + Ipamorelin Blend works
The blend pairs two distinct mechanisms: CJC-1295 agonizes the GHRH receptor while ipamorelin agonizes the growth-hormone secretagogue (ghrelin) receptor. Because GHRH analogs and GHRPs act on separate pituitary pathways, their combined administration is studied for potentially synergistic, greater-than-additive GH release. Ipamorelin's selectivity is intended to add GH stimulation without notably raising cortisol or prolactin.
How Ipamorelin works
Ipamorelin is an agonist of the growth-hormone secretagogue receptor (GHS-R1a, the ghrelin receptor), mimicking ghrelin to stimulate GH release from the anterior pituitary. It acts on the pituitary and hypothalamus to promote a pulsatile release of growth hormone. Unlike some other GHRPs, it is reported to be highly selective, releasing GH without significantly stimulating ACTH, cortisol, or prolactin at effective doses.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
CJC-1295 + Ipamorelin Blend
Ipamorelin
What sets each apart
CJC-1295 + Ipamorelin Blend
Unlike single-agent GHRH analogs or GHRPs, this is a combination formulation designed to engage both the GHRH and ghrelin receptor pathways simultaneously.
Ipamorelin
Among GHRPs, ipamorelin is noted for its selectivity — stimulating GH release without the appetite, cortisol, and prolactin elevations associated with GHRP-6 and hexarelin.
Documented together as a research blend
Cross-referenced for research context — not a usage or combination recommendation.
Frequently asked questions
What is the CJC-1295 / Ipamorelin blend?
This is a combination research preparation containing both CJC-1295 (a GHRH analog) and ipamorelin (a selective GHRP / ghrelin-receptor agonist) in a single vial. It formalizes the most widely referenced GH-secretagogue research pairing into one product.
Why are CJC-1295 and ipamorelin combined?
The two act on different receptors: CJC-1295 on the GHRH receptor and ipamorelin on the ghrelin receptor (GHS-R1a). Stimulating both pathways simultaneously produces a synergistic GH pulse larger than either compound alone, which is the rationale for the blend in research settings.
Does the blend use CJC-1295 with DAC or without DAC?
Blends vary by source. Many CJC-1295 + ipamorelin blends use the no-DAC (Mod GRF 1-29) form so that both components are short-acting and produce a clean pulsatile profile, but some use the DAC version for sustained GHRH tone. The specific form should be confirmed on the product's COA.
What is ipamorelin and what class of compound is it?
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (a ghrelin/GHS-R1a receptor agonist). It is studied as one of the most selective GHRPs, stimulating pulsatile GH release from the anterior pituitary with minimal effect on cortisol, prolactin, or ACTH in research models.
How does ipamorelin differ from GHRP-2 and GHRP-6?
All three activate the ghrelin receptor (GHS-R1a), but ipamorelin is the most selective: in the research literature it drives GH release without the appetite stimulation seen with GHRP-6 or the cortisol/prolactin elevation associated with GHRP-2. This selectivity is why it is frequently used as a reference GHRP in study design.
Why is ipamorelin commonly studied alongside a GHRH analog like CJC-1295?
Ipamorelin (a GHS-R agonist) and a GHRH analog such as CJC-1295 or sermorelin act on two different receptor pathways. Research protocols pair them because combined GHRH + GHRP stimulation produces a synergistic, amplified GH pulse greater than either compound alone.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.